» Articles » PMID: 20133001

Advanced Glycation End Products Induce Production of Reactive Oxygen Species Via the Activation of NADPH Oxidase in Murine Hepatic Stellate Cells

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2010 Feb 6
PMID 20133001
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Advanced glycation end products are known to play an important role in the metabolic syndrome and were recently suggested to contribute to liver fibrosis development. However, little is known about the effect of advanced glycation end products on hepatic stellate cells, the major contributors to liver fibrosis development. We therefore studied the effect of advanced glycation end products on reactive oxygen species generation, a main feature for the activation hepatic stellate cells.

Methods: Three different types of advanced glycation end products were generated by BSA incubation with different substrates. The presence of advanced glycation end product receptors was examined by RTq-PCR, immunofluorescence and western blotting. Reactive oxygen species production was measured using DCFH-DA.

Results: Hepatic stellate cells express five advanced glycation end product receptors: Galectin-3, CD36, SR-AI, SR-BI and RAGE. All receptors, except SR-BI, showed up-regulation during HSC activation. All three advanced glycation end product types induced reactive oxygen species generation. DPI and NSC, a NADPH oxidase and a Rac1 inhibitor respectively, inhibited reactive oxygen species production. Rottlerin, a molecule often used as a PKCdelta inhibitor, also abrogated reactive oxygen species production. SiRNA mediated knockdown of p47(phox), Rac1 and PKCdelta decreased reactive oxygen species production induced by advanced glycation end products, establishing a role for these proteins in reactive oxygen species induction.

Conclusions: The demonstration of advanced glycation end product-induced reactive oxygen species generation in hepatic stellate cells unveils a potential new route through which advanced glycation end products induce liver fibrosis in the metabolic syndrome.

Citing Articles

Comparison of Metabolic and Hormonal Profiles between Low-Advanced Glycation End Products (AGEs) and Standard AGEs-Containing Weight-Loss Diets in Overweight Phenotype-A PCOS Patients: A Randomized Clinical Trial.

Ozdemir M, Mumusoglu S, Bilgic P Reprod Sci. 2025; .

PMID: 39953370 DOI: 10.1007/s43032-025-01808-8.


Metabolism of hepatic stellate cells in chronic liver diseases: emerging molecular and therapeutic interventions.

Yan M, Cui Y, Xiang Q Theranostics. 2025; 15(5):1715-1740.

PMID: 39897543 PMC: 11780521. DOI: 10.7150/thno.106597.


Remodeling of the Intracardiac Ganglia During the Development of Cardiovascular Autonomic Dysfunction in Type 2 Diabetes: Molecular Mechanisms and Therapeutics.

Evans A, Li Y Int J Mol Sci. 2024; 25(22).

PMID: 39596529 PMC: 11594459. DOI: 10.3390/ijms252212464.


Advanced glycation end products promote ROS production via PKC/p47 phox axis in skeletal muscle cells.

Suzuki S, Hayashi T, Egawa T J Physiol Sci. 2024; 74(1):51.

PMID: 39369187 PMC: 11452979. DOI: 10.1186/s12576-024-00944-1.


Comprehensive evaluation of the mechanism of human adipose mesenchymal stem cells ameliorating liver fibrosis by transcriptomics and metabolomics analysis.

Ji G, Zhang Z, Wang X, Guo Q, Zhang E, Li C Sci Rep. 2024; 14(1):20035.

PMID: 39198546 PMC: 11358327. DOI: 10.1038/s41598-024-70281-1.